Faculty Disclosures

Dr. Arias is a graduate of Michigan State University’s College of Human Medicine (2001), and he completed his residency in psychiatry as well as a master’s degree in clinical and translational research at the University of Connecticut Health Center. He was on the faculty at UCONN School of Medicine for 5 years and then was a full-time faculty member at Yale University School of Medicine for 7 years in the department of psychiatry before joining VCU in 2018 as an associate professor and the Associate Division Chair for Addiction Psychiatry.  He is board certified in Psychiatry by the ABPN and board certified in addiction medicine by ABPM.

Dr. Arias has logged many hours teaching to medical students, residents, and fellows at all three universities for which he was on the faculty. He has developed several innovative teaching programs such as an elective course in psychiatric and addiction pharmacogenetics (at Yale), and a tele-addictions buprenorphine training clinic for fellows. He created the didactic program for the addiction medicine fellowship at VCU Health. He currently teaches as an attending at the MOTIVATE outpatient addiction clinic and as the program director of the Addiction Medicine Fellowship Program. He received a training grant from HRSA to expand the fellowship training program.

Saul Levin, MD, MPA, FRCP-E, FRCPsych, is the Chief Executive Officer and Medical Director of the American Psychiatric Association (APA). Before assuming this role in October 2013, Dr. Levin led the District of Columbia Department of Health (DOH). Where he was responsible for the health of the nation’s Capitol. Prior, he was the President and CEO of the Medical Education of South African Blacks (MESAB), an anti-staff Apartheid Education Trust providing scholarships to black students entering the medical field; American Medical Association Vice President for Science Medicine + Public Health and DHHS (USA) Special Appointee to ADAMHSA/ NIAMH/ NIDA/ NIAAA and SAMHSA 

Mark Niciu, M.D. Ph.D., is an Assistant Professor of Psychiatry at the University of Iowa Health Care, affiliated with the Iowa Neuroscience Institute. He is an expert in the evaluation and treatment of major depressive disorder (MDD) and bipolar disorder, especially glutamate-based treatments including racemic ketamine infusions and intranasal esketamine insufflations. His translational and clinical laboratory studies focus on the genetic, molecular, and cellular mechanisms of disease in major mood disorders, pharmacological response to antidepressant medications, and the identification, replication and dissemination of treatment response biomarkers. He has over 60 peer-reviewed publications and has received both federal and foundational research funding to support his past and current research.

Dr. David Oslin is a Professor of Psychiatry and Vice Chair for Veterans Health at the Cpl Michael J Crescenz (Philadelphia) Veterans Affairs Medical Center and the Perelman School of Medicine at the University of Pennsylvania. Dr. Oslin is the Director of the VISN 4 Mental Illness, Research, Education, and Clinical Center (MIRECC), Director of the Crescenz NODES program, and the Chief of Behavioral Health at the Philadelphia VAMC. The MIRECC supports research on implementing precision mental health care and facilitates a number of research projects for post-doctoral fellows and faculty. Dr. Oslin is the author of over 300 research publications and 30 chapters, books, or editorials. Dr. Oslin's research portfolio includes studies aimed to improve access to behavioral health care, implementing measurement based mental health care, and the study of pharmacogenetics of addiction and depression treatment.

Dr. Pandurangi trained in psychiatry at the National Institute of Mental Health, India, Upstate Medical Center, SUNY, Syracuse, NY and Columbia University NY, NY. He was a full time faculty at Virginia Commonwealth University and until retirement served as Professor of Psychiatry and Vice Chair of the Department of Psychiatry at VCU. His education and research expertise spawns across multiple areas including schizophrenia, refractory depression, bipolar disorder, tardive dyskinesia, brain imaging, nosology, psychopharmacology and brain stimulation therapies including ECT, TMS, VNS, DBS and Ketamine infusion. On these subjects, he has published over 250 major and minor articles and book chapters. In recognition of his valuable contributions, Dr. Pandurangi has received more than 25 national and international awards

Roxanne Sholevar is a psychiatrist practicing in Boston, MA. She graduated from psychiatry residency at VCU in 2020 and completed a fellowship in consultation-liaison psychiatry on the psychosocial oncology and palliative care track at Brigham and Women's/Dana Farber Cancer Institute in Boston. She now works part time at Dana Farber seeing adult patients with cancer and has a faculty appointment at Harvard Medical School, where she supervises CL fellows liaisonship to the inpatient palliative care unit. She is in private practice where she sees healthy adults for psychodynamic psychotherapy and is in her first year of advanced psychoanalytic psychotherapy training at the Boston Psychoanalytic Society and Institute. She completed the Certificate in Psychedelic Therapies and Research at the California Institute of Integral Studies in 2021 and joined a research team at Dana Farber, where she is a therapist in a clinical trial examining the use of psilocybin for treatment of demoralization in hospice patients. Other significant professional activities include qualitative research on attitudes and perspectives on psychedelic therapies among healthcare professionals and development of a graduate medical curriculum around psychedelic therapies for HMS-affiliated psychiatry residents.